-

Atalanta Therapeutics to Present at Stifel 3rd Annual CNS Day

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, announced today that Alicia Secor, president and chief executive officer, and Aimee L. Jackson, Ph.D., chief scientific officer, are scheduled to participate virtually in an analyst-led fireside chat at the Stifel 3rd Annual CNS Day on Thursday, April 1, 2021 at 1:30 pm ET.

About Atalanta Therapeutics

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. Atalanta was founded in 2018 by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. Atalanta is headquartered in Boston, Mass. For more information, visit www.atalantatx.com and follow us on Twitter and LinkedIn.

Contacts

Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com

Industry:

Atalanta Therapeutics

Release Versions
English

Contacts

Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com

More News From Atalanta Therapeutics

Atalanta Therapeutics Announces Leadership Transitions

BOSTON--(BUSINESS WIRE)--Joanne Kotz joins Atalanta as Chief Executive Officer, with proven experience building and scaling innovative platform-based companies....

Atalanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the publication of preclinical data in the journal Epilepsia demonstrating proof-of-mechanism of its investigational di-siRNA therapy, ATL-201, in a mouse model of KCNT1-related epilepsy. Durable seizure suppression and behavioral improvements were observed over 6 months, with favorable tolerability. The company plans to submit an...

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trials

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, funds...
Back to Newsroom